Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 22 Sept 2023

Morris Sarah A, Moore Donald C, Musselwhite Laura W, Lopes Karine Eboli, Hamilton Alicia, Steuerwald Nury, Hanson Sarah L, Larck Chris, Swift Kristen, Smith Mathew, Kadakia Kunal C, Chai Seungjean, Hwang Jimmy J, Patel Jai N

Abstract excerpt

PURPOSE: To describe the implementation of an in-house genotyping program to detect genetic variants linked to impaired dihydropyrimidine dehydrogenase (DPD) metabolism at a large multisite cancer center, including barriers to implementation and mechanisms to overcome barriers to facilitate test adoption. SUMMARY: Fluoropyrimidines, including fluorouracil and capecitabine, are commonly used chemotherapy agents in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Cancer Treatments and Studies

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Genotype

Share to Neoplasms

Share to Pharmacogenetics and Drug Metabolism

Source

Identifiers

PMID: 37235983
DOI: 10.1093/ajhp/zxad117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.PMID 37235983Read ↗

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity Read ↗

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity Read ↗

Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United StatesSemantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.Semantic proximity Read ↗

Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.Semantic proximity Read ↗

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementationSemantic proximity Read ↗

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer centerSemantic proximity Read ↗

Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic FluoropyrimidineSemantic proximity Read ↗

Feasibility of DPYD Genotyping in Australian Cancer PatientsSemantic proximity Read ↗

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Semantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.